Urology Research and Publications

Research

The Division of Urology is actively involved in clinical and basic science research at the University of Connecticut Health Center campus. We collaborate with basic scientists in many fields. The new Academic Research building provides ample opportunity for laboratory studies as well as support for clinical work. Each member of our faculty is dedicated to the advancement of urologic practice through research and routinely presents at urologic conferences. The division also participates in many local and national clinical trials and can provide patients with information on ongoing studies at other institutions.

Publications

Recent

1. Taylor JA, Moss E and Goluboff ET: Minimally Invasive Therapies for Benign Prostatic Hyperplasia. Hospital Physician, Urology Board Review Manual 1999; 7(2).

2. Taylor JA and Lowe FC. Alternative therapies for benign prostatic hyperplasia. In: Gomella LG ed. The 5-Minute Urology Consult. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.

3. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobson SJ. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer, June 15, 2001; 91(12): 2302-14.

4. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality of Life Outcomes Following Primary Androgen Deprivation Therapy: Results from the Prostate Cancer Outcomes Study. J Clinical Oncology, 2001; 19(17): 3750-3757.

5. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid? J Natl Cancer Inst, 2001; 93(23): 1822-1823.

6. Harlan LC, Potosky AL, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors Associated with Initial Therapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst, 2001; 93(24): 1864-1871.

7. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural Experiment Examining Impact of Aggressive Screening and Treatment on Prostate Cancer Mortality in Two fixed Cohorts from Seattle area and Connecticut. BMJ, 2002; 325(7367): 740.

8. Shin D, Honig SC. Cost Effectiveness of Male Infertility Treatment. Urologic Clinics of North America. Elsevier, Nov 2002.

9. Pan D, Watson HK, Swigart C, Thomson G, Honig SC, Narayan D. Microarray gene analysis and expression profiles of Dupuytren’s contracture. Ann Plast Surg, 2003;50:618-622.

10. Taylor JA, Gancarczyk KJ, Fant GV and McLeod DG. Increasing the Number of Core Samples Taken at Prostate Needle Biopsy Enhances the Detection of Clinically Significant Prostate Cancer. Urology, 2002; 60(5): 841-845.

11. Samson D, Seidenfeld J, Wilt T, Schmitt B, Albertsen PC. Systematic Review and Meta-Analysis of Monotherapy Compared with Combined Androgen Blockade for Advanced Prostate Cancer. Cancer, 2002; 95(2):361-376.

12. Hsieh K, Taylor JA and Albertsen PC. Lower Urinary Tract Symptoms in the Older Male. Connecticut Medicin, 2003; 67(8): 487-490.

13. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of Rising Prostate Specific Antigen as a Predictor of Prostate Cancer Death Following Treatment of Localized Prostate Cancer with Either Surgery or Radiation. J Urol, 2004; in press.

14. Taylor JA, Kao TK, Albertsen PC and Shabsigh R. Bicycle Riding and It’s Relationship to the Development of Erectile Dysfunction. J Urol, 2004; in press.

Selected

1. Fleming C, Wasson J, Albertsen PC, Barry M, and the Prostate PORT. A Decision Analysis of Alternative Treatment for Clinically Localized Prostate Cancer. JAMA, 1993, 269:2650-2658.

2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The Role of Increasing Detection in the Rising Incidence of Prostate Cancer. JAMA, 1995, 273:548-552.

3. Albertsen PC*, Fryback DG, Storer DE, Kolon TF, Fine J. Long-term Survival Among Men With Conservatively Treated Localized Prostate Cancer. JAMA, 1995, 274:626-631.

4. Albertsen PC*, Fryback DG, Storer BE, Kolon TF, Fine J. The Impact of Co-morbidity on Life Expectancy Among Men with Localized Prostate Cancer. J Urol, 1996, 156:127-132.

5. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Followup Prostate Cancer Treatments After Radical Prostatectomy - a Population Based Study. J Nat Cancer Inst, 1996, 88:166-173.

6. Welch WG, Albertsen PC, Nease RF, Bubocz TA, Wasson JH. Estimating Treatment Benefits for the Elderly - the Effect of Competing Risks. Ann Int Med, 1996, 124:577-584.

7. Albertsen PC*, Nease RF Jr., Potosky AL. Assessment of Patient Preferences Among Men with Prostate Cancer. J Urol, 1998, 159: 158-163.

8. Albertsen PC*, Hanley JA, Gleason DF, Barry MJ. A Competing Risk Analysis of Men age 55-74 years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer. JAMA, 1998; 280:975-980.

9. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe LH, Albertsen PC, Roehborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia. N Eng J Med, 1998, 338:557-563.

10. Potosky AL, Harlan LC. Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff M, Deapen D, Stephenson RA, Legler J, Gerrans CE, Talcott JA, Litwin MS. Commentary: Assessment of Prostate Cancer Practice Patterns and Quality of Life: The Prostate Cancer Outcomes Study. J Natl Canc Inst, 1999; 91:1719-1724.

11. Albertsen PC*, Walters S, Hanley JA. A Comparison of Cause of Death Determination Among Men Previously Diagnosed with Prostate Cancer and Dying in Either 1985 or 1995. J Urol, 2000;163:519-523.

12. Sanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer: The Prostate Cancer Outcomes Study. JAMA, 2000; 283:354-360.

13. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-Therapy Androgen Suppres- sion in Men with Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Ann Int Med, 2000, 132:566-577.

14. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS. Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst, 2000; 91:1719-1724.

15. Albertsen PC*, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA. Positive Yield of Imaging Studies in the Evaluation of Men with Newly Diagnosed Prostate Cancer: A Population Based Analysis. J Urol, 2000;163:1138-1143.

16. Fowler FJ, McNaughton-Collins M, Albertsen PC, Zeitman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA, 2000; 283:3217-3222.

17. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health Outcomes After Radical Prostatectomy or Radiotherapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study (PCOS). J Natl Cancer Inst, 2000; 92:1582-1592.